Puma Biotechnology, Inc. (PBYI) Reports Q3 Loss of $1.29
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street lower on AI spending jitters; oil prices rebound
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts PBYI Hot Sheet
Join SI Premium – FREE
Puma Biotechnology, Inc. (: PBYI) reported Q3 EPS of ($1.29), versus ($0.09) reported last year. Revenue for the quarter came in at $0 versus the consensus estimate of $0 .
For earnings history and earnings-related data on Puma Biotechnology, Inc. (PBYI) click here.
For earnings history and earnings-related data on Puma Biotechnology, Inc. (PBYI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Scotiabank Names Top Utility Stocks Amid Data Center Growth
- UBS Reiterates Neutral Rating on Nike (NKE) on Expected Pace of Earnings Recovery
- ARMOUR Residential (ARR) PT Lowered to $14.50 at B.Riley
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
